CVR number 41381515
Industry 86.2100 General medical practice activities

LÆGERNES HUS. LANGESKOV ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  0.5% 0.5% 0.5% 0.5% 0.5%  
Bankruptcy risk  2.8% 2.9% 3.2% 2.7% 2.9%  
Credit score (0-100)  58 57 55 60 58  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  375 324 319 388 319  
EBITDA  375 324 319 388 319  
EBIT  342 291 287 355 286  
Pre-tax profit (PTP)  224.3 261.7 251.0 321.6 246.2  
Net earnings  160.6 199.5 189.5 244.5 183.8  
Pre-tax profit without non-rec. items  224 262 251 322 246  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  2,733 2,700 2,667 2,634 2,602  
Shareholders equity total  1,014 1,063 1,103 1,197 1,221  
Interest-bearing liabilities  1,880 1,791 1,700 1,610 1,518  
Balance sheet total (assets)  2,905 2,865 2,814 2,826 2,781  
Net Debt  1,756 1,674 1,602 1,453 1,372  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  375 324 319 388 319  
Gross profit growth  0.7% -13.5% -1.4% 21.4% -17.7%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,905 2,865 2,814 2,826 2,781  
Balance sheet change%  0.4% -1.4% -1.8% 0.4% -1.6%  
Added value  374.7 324.1 319.5 387.7 319.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -65 -65 -65 -65 -65  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  91.3% 89.9% 89.8% 91.6% 89.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  11.8% 10.4% 10.1% 12.6% 10.2%  
ROI %  12.4% 10.4% 10.1% 12.7% 10.3%  
ROE %  15.9% 19.2% 17.5% 21.3% 15.2%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  34.9% 37.1% 39.2% 42.4% 43.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  468.6% 516.4% 501.5% 374.6% 430.1%  
Gearing %  185.4% 168.4% 154.2% 134.4% 124.3%  
Net interest  0 0 0 0 0  
Financing costs %  6.8% 2.0% 2.0% 2.0% 2.6%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.7 1.6 1.4 1.7 1.3  
Current Ratio  1.7 1.6 1.4 1.7 1.3  
Cash and cash equivalent  124.2 116.8 98.1 157.0 146.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  71.9 64.0 45.3 81.0 45.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0